Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis

被引:15
|
作者
Castro, Rodolfo [1 ,2 ]
Perazzo, Hugo [3 ]
Artilles Mello Mendonca de Araujo, Leticia [1 ]
Gutierres, Isabella Goncalves [1 ]
Grinsztejn, Beatriz [3 ]
Veloso, Valdilea G. [3 ]
机构
[1] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ Sergio Arouca, Rio De Janeiro, RJ, Brazil
[2] Univ Fed Estado Rio de Janeiro, Inst Saude Colet, Rio De Janeiro, RJ, Brazil
[3] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil
来源
PLOS ONE | 2020年 / 15卷 / 02期
关键词
REAL-WORLD; CARE; SOFOSBUVIR; SAFETY; REGIMENS; THERAPY; PROGRAM;
D O I
10.1371/journal.pone.0229143
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Direct-acting agents (DAAs) for hepatitis C virus (HCV) treatment are safe and highly effective. Few studies described the sustained virologic response rates of treatment conducted by non-specialists. We performed a systematic review and meta-analysis to evaluate the effectiveness of decentralized strategies of HCV treatment with DAAs. PubMed, Embase, Scopus and LILACS were searched until March-2019. Studies were screened by two researchers according to the following inclusion criteria: HCV treatment using DAAs on real-life cohort studies or clinical trials conducted by non-specialized health personnel. The primary endpoint was the sustained virologic response rate at week 12 after the end-of-treatment (SVR12), which is binary at the patient level. Data were extracted in duplicate using electronic-forms and quality appraisal was performed with the NIH Quality Assessment Tool. Heterogeneity was assessed by I-2 statistics. Random-effects meta-analysis models were used for pooling SVR12 rates. Publication bias was assessed using funnel plots. Among the 130 selected studies, nine papers were included for quantitative synthesis. The quality-appraisal was good for two, fair for three and poor for four studies. The pooled relative risk (RR) of SVR12 was not statistically different between decentralized strategy and treatment by specialists [RR = 1.05; 95% confidence interval (95% CI): 0.98-1.1; I-2 = 45% (95% CI: 0-84%), p = 0.145]. SVR12 rate for decentralized HCV treatment was 81% [SVR12 95% CI: 72-89%; I-2 = 93% (95% CI: 88-96%)] and 95% [SVR12 95%CI: 92-98%; I-2 = 77% (95% CI: 52-89%)] with intention to treat analysis and per-protocol analysis, respectively. SVR12 rates using DAAs managed by non-specialized health personnel were satisfactory and similar to those obtained by specialists. This new delivery strategy can improve access to HCV treatment, especially in resource-limited settings.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Effectiveness of Direct-acting Antivirals for the Treatment of Chronic Hepatitis C in Rwanda: A Retrospective Study
    Nsanzimana, Sabin
    Penkunas, Michael J.
    Liu, Carol Y.
    Sebuhoro, Dieudonne
    Ngwije, Alida
    Remera, Eric
    Umutesi, Justine
    Ntirenganya, Cyprien
    Mugeni, Soline D.
    Serumondo, Janvier
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 73 (09) : E3300 - E3307
  • [42] Effectiveness of Direct-Acting Antivirals in Treatment of Elderly Egyptian Chronic Hepatitis C Patients
    Kamel, Shimaa
    Elessawy, Hagar
    Ashraf, Ossama
    Elbaz, Ahmed
    Dabbous, Hany
    El-Sayed, Manal
    Ali, Safaa
    Kamel, Heba
    [J]. GASTROENTEROLOGY INSIGHTS, 2021, 12 (03) : 336 - 346
  • [43] Crushing and Splitting Direct-Acting Antivirals for Hepatitis C Virus Treatment: A Case Series and Literature Review
    Whelchel, Kristen
    Zuckerman, Autumn D.
    Koren, David E.
    Derrick, Caroline
    Bouchard, Jeannette
    Chastain, Cody A.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (11):
  • [44] New direct-acting antivirals for the treatment of chronic hepatitis C
    Jeong, Sook-Hyang
    [J]. JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2015, 58 (12): : 1154 - 1158
  • [45] Safety of direct-acting antivirals in the treatment of chronic hepatitis C
    Ridruejo, Ezequiel
    [J]. EXPERT OPINION ON DRUG SAFETY, 2014, 13 (03) : 307 - 319
  • [46] Cost-effectiveness of direct-acting antivirals for chronic hepatitis C
    Gaby Sroczynski
    Uwe Siebert
    [J]. Nature Reviews Gastroenterology & Hepatology, 2013, 10 : 572 - 574
  • [47] Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis
    Kim, Nicole J.
    Vutien, Philip
    Cleveland, Erin
    Cravero, Anne
    Ioannou, George N.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (07) : 1723 - 1738
  • [48] Benefits of Direct-Acting Antivirals for Hepatitis C
    Lok, Anna S.
    Chung, Raymond T.
    Vargas, Hugo E.
    Kim, Arthur Y.
    Naggie, Susanna
    Powderly, William G.
    [J]. ANNALS OF INTERNAL MEDICINE, 2017, 167 (11) : 812 - +
  • [49] Hepatitis C virus core antigen as a possible alternative for evaluation of treatment effectiveness after treatment with direct-acting antivirals
    Lucejko, M.
    Tomasiewicz, K.
    Olczak, A.
    Tudrujek-Zdunek, M.
    Halota, W.
    Jelski, W.
    Donica, H.
    Krintus, M.
    Mroczko, B.
    Flisiak, R.
    [J]. BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2019, 76 (04) : 190 - 194
  • [50] Targeting Hepatitis C With Direct-Acting Antivirals
    Pennell, Laurie
    LaPreze, Jennifer
    [J]. US PHARMACIST, 2023, 48 (03) : 22 - 27